ClinicalTrials.gg

Program

biafungin acetate

Also written as “Rezafungin Acetate” and “Rezafungin Acetate / Co Trimoxazole”.

Its studies are mostly in Pulmonary Aspergillosis · Invasive Fungal Infections · Pneumonia, Pneumocystis, led by Mundipharma.

Furthest: phase 2, since Apr 4, 20233 company-led studies, 2 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mundipharma32 open or runningphase 2since Apr 4, 2023Sep 1, 2022Nov 30, 2026phase 2 · NCT06794554

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2022First study: phase 1 study in Invasive Fungal InfectionsFirst studyNCT05534529 · 32 enrolled · Germany, Spain, United Kingdom
  2. Apr 4, 2023Phase 2 study in Pneumonia, PneumocystisNCT05835479 · 50 planned · South Africa
  3. Nov 26, 2024Phase 2 study in Chronic Pulmonary AspergillosisNCT06794554 · 60 enrolled · Austria, Belgium, France and more

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Chronic Pulmonary AspergillosisNCT06794554

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Candida inhibitor”ChEMBL 37, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06794554Chronic Pulmonary Aspergillosis · Austria, Belgium, France and more2Active, not recruitingNov 30, 202660
NCT05835479Pneumonia, Pneumocystis · South Africa2RecruitingMay 202550
NCT05534529Invasive Fungal Infections · Germany, Spain, United Kingdom1TerminatedMay 23, 202432

How it is read

Names in the registry

  • “Rezafungin Acetate”, 2 entries
  • “Rezafungin Acetate / Co Trimoxazole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.